SEC Form 4/A · accession 0001179110-16-032503
SUNESIS PHARMACEUTICALS INC · SNSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Daniel N Swisher Jr.
Officer — President and CEO · Director
Period of report
Nov 30, 2016
Accepted (ET)
Dec 6, 2016 · 7:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001061027
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.00 | Nov 30, 2016 | A | 240,000 | A | — | Nov 30, 2026 | Common Stock | 240,000 | 240,000 | D |
Explanation of responses
- F1Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020.
Remarks
This amendment is being filed to correct the exercise price of the option grant so that it reflects the adjusted closing price on November 30, 2016 of $4.00.